Edwards Lifesciences Corporation
Edwards Lifesciences Corporation’s revenue for fiscal 2025 (year ended December 2025) was $6.1 billion, up 11.5% from fiscal 2024. In the quarter to June 2026, revenue grew 13.6%, EPS fell 26.3%, free cash flow grew 142.8% and total debt was flat, each against the same quarter a year earlier. Member of the S&P 500; revenue growth for three consecutive years.
Follow EW
Edwards Lifesciences Corporation (EW) Revenue
Edwards Lifesciences Corporation's revenue for fiscal 2025 was $6.1B, up 11.5% from $5.4B in fiscal 2024. Over the twelve months to 30 June 2026 it was $6.5B. Over the past ten years it has ranged from $2.5B (fiscal 2015) to $6.1B (fiscal 2025) — the current reading is the highest in ten years. Revenue has risen for 3 consecutive fiscal years. Edwards Lifesciences Corporation ranks 9th of 140 Medical Devices companies by revenue.
Revenue, annual
Embed this chart
Annual newest first
| Period | Revenue | Change |
|---|---|---|
| FY2025 | $6.1B | 11.55% |
| FY2024 | $5.4B | 8.57% |
| FY2023 | $5.0B | 12.23% |
| FY2022 | $4.5B | (14.69%) |
| FY2021 | $5.2B | 19.29% |
| FY2020 | $4.4B | 0.88% |
| FY2019 | $4.3B | 16.79% |
| FY2018 | $3.7B | 8.37% |
| FY2017 | $3.4B | 15.91% |
| FY2016 | $3.0B | 18.85% |
Quarterly newest first
| Period | Revenue | Change |
|---|---|---|
| Jun 2026 | $1.7B | 5.60% |
| Mar 2026 | $1.6B | 5.03% |
| Dec 2025 | $1.6B | 1.06% |
| Sep 2025 | $1.6B | 1.36% |
| 42 more quarters | Free account |
Against its own ten years
Revenue against peers
| Company | Revenue |
|---|---|
| MDT Medtronic PLC compare | $37.5B |
| SYK Stryker Corporation compare | $25.8B |
| GEHC GE HealthCare Technologies Inc. compare | $21.3B |
| BSX Boston Scientific Corporation compare | $21.0B |
| PHG Koninklijke Philips N.V. compare | $20.6B |
| ZBH Zimmer Biomet Holdings, Inc. compare | $8.5B |
| EW Edwards Lifesciences Corporation | $6.5B |
| STE STERIS plc compare | $6.0B |
| DXCM DexCom, Inc. compare | $5.0B |
What Revenue is
Revenue tells an investor how much a company brought in from selling its goods and services over a period, before any costs are taken out.
Reported line item
More on EW
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement